Off-target confirmation service

Confirm your on- and off‑target edits, from coordinates to report.

You define the targets. We design the panel, run LockSeq in our lab in Solna, Stockholm and deliver an analyzed report in 15 business days. No instrument investment, no bioinformatics overhead.

Request a quote See a sample report

LockSeq report · results

Illustrative data

290 / 300

sites reportable

off-target edit found

Site	Edited	Control	Call
DP-001 on-target	71.3%	0.00%	Edited
DP-187 off-target	0.23%	0.00%	Edited
DP-069 off-target	0.52%	0.58%	In control
DP-004 off-target	0.00%	0.00%	No variant

Mean variant frequency, 3 replicatesView full sample report →

The regulatory context

FDA draft guidance puts off‑target confirmation before the IND

The FDA's April 2026 draft guidance on genome editing safety asks for confirmatory testing at nominated off‑target sites, names probe‑based sequence enrichment among the methods, and expects these studies done before the original IND.

As panels grow, keeping sensitivity and complete target coverage gets harder. Missing sites are data blind spots that can turn into delays and regulatory risk. That confirmation step is what LockSeq does.

Nominate

Candidate sites from your nomination assay or in silico prediction.

Confirm with LockSeq

An independent, targeted readout of every nominated site in your edited samples.

Report

Edit frequencies per site, ready for your safety package.

How it works

What's included in every LockSeq study

An end-to-end service: you focus on your program, we deliver high-confidence edit detection.

01 · Scoping

Project scoping

We review your edit design, gRNAs and nominated off‑target coordinates, and add in silico nomination where needed. Usually within 24 hours.

02 · Panel

Panel design

Padlock probes for all your on‑ and off‑target loci, designed for 1,000+ sites per reaction. Add new targets later without redesigning the panel.

03 · Lab

Sequencing

Library prep and sequencing in our lab in Solna, Stockholm, on Illumina, MGI or Oxford Nanopore.

04 · Report

Consensus report

UMI-corrected VAF per site with indel profiling, coverage charts and raw data (FASTQ + BAM). 15 business days from DNA receipt.

#1 — PROJECT SCOPING

We review your edit design, gRNA sequences, and nominated off-target coordinates. Where needed, we can supplement with in silico nomination. Turnaround: Usually within 24 hours from first contact to project specification.

#2 — PANEL CUSTOMIZATION

We design padlock probes for all your on- and off-target loci — up to 1,000+ sites per reaction. Probes are validated in silico before synthesis.

Mix-and-match of new targets across development stages without panel redesign.

#3 — TECHNICAL EXECUTION

LockSeq library preparation and sequencing are performed in our Stockholm laboratory. Illumina and Oxford Nanopore platforms confirmed.

#4 — CONSENSUS REPORTING

You receive a UMI-corrected variant allele frequency report with indel profiling, coverage uniformity charts, and raw data (FASTQ + BAM). Standard turnaround: 15 business days from DNA receipt.

0.1%

VAF detection limit

1,000+

sites per reaction, by design

15 days

business days, DNA receipt to report

platforms: Illumina, MGI & ONT

Why LockSeq

Built so a sequencing error never reads as an off‑target

High-confidence edit detection

Every captured molecule gets a UMI before amplification, and reads are collapsed into one consensus call per molecule. Confident calls down to 0.1% VAF, with each site’s limit set by its own coverage.

Every site clearly reported

Sites we can't design for are flagged before you send samples. Every other site gets a clear status in the report, including any that drop out in the lab.

Small and large panels, same workflow

From a single site to large off‑target panels. Add targets without redesigning the assay.

High-Confidence Edit Detection

LockSeq uses gap-fill ligation to capture target molecules prior to amplification. UMI-based consensus sequencing suppresses technical errors, enabling confident detection of edits down to 0.1% VAF across panels exceeding 1,000 targets.

Fewer Dropouts. Better Coverage.

LockSeq is designed to minimize target dropout in highly multiplexed workflows. By reducing assay complexity and potential molecular interactions, the platform improves target representation and supports more complete genomic characterization across large panels.

One Workflow. Any Scale.

Reconfigure targets without assay redesign. LockSeq supports everything from single-site confirmation to >1,000-plex off-target characterization in a single workflow, with demonstrated compatibility across Illumina and ONT.